Showing 3641-3650 of 9300 results for "".
- Venous Thromboembolism Risk Lower in AD Patients: Analysishttps://practicaldermatology.com/news/venous-thromboembolism-risk-lower-in-ad-patients-analysis/2462196/A retrospective, observational analysis in the Journal of the American Academy of Dermatology showed that patients with atopic dermatitis (AD) do not have an increased risk for venous thromboembolism (VTE) compared with other immune-mediated inflammatory diseases. The analysis compared VTE incide…
- Analysis: Vegetarian Diet during Pregnancy Lowers Risk of AD in Childrenhttps://practicaldermatology.com/news/association-between-a-maternal-vegetarian-diet-during-pregnancy-and-the-occurrence-of-atopic-dermatitis-in-children/2462188/A new study published in Pediatric Allergy and Immunology suggested that a vegetarian diet during pregnancy was associated with a reduced risk for atopic dermatitis (AD) in children. Researchers looking at the Taiwan Birth Cohort Study (TBCS) database analyzed 24,200 mother-child pairs, and compl…
- Kymera Update: First Patient Dosed in Phase 2 AD Clinical Trial of KT-474, a First-in-Class Investigational IRAK4 Degraderhttps://practicaldermatology.com/news/kymera-update-first-patient-dosed-in-phase-2-ad-clinical-trial-of-kt-474-a-first-in-class-investigational-irak4-degrader/2462177/The first patient has been dosed in the Phase 2 clinical trial (ADVANTA) evaluating KT-474 in AD, generating a $15 million milestone payment under its collaboration with Sanofi. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflammatory diseases, i…
- Journey’s Rosacea Therapy Clears Pre-NDA Hurdlehttps://practicaldermatology.com/news/journeys-rosacea-therapy-clears-pre-nda-hurdle/2462176/Journey Medical Corporation has successfully completed its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) to treat rosacea. The company is on track to submit an NDA to the FDA for DFD-2…
- Mathematical Dermatology: The Dawn of a New Multidisciplinary Research Fieldhttps://practicaldermatology.com/news/mathematical-dermatology-research-on-csu-may-sire-a-new-specialty/2462167/Chronic spontaneous urticaria (CSU) has a clear and visible appearance on the skin surface, but the mechanism underlying the various shapes of wheals in vivo remains largely obscured. To address this, a research group led by Professor Sungrim Seirin-Lee at Kyoto University Institute for the Advan…
- Revealed: How Chronological Aging Affects EV Production by Human Keratinocyteshttps://practicaldermatology.com/news/revealed-how-chronological-aging-affects-ev-production-by-human-keratinocytes/2462166/Aging modulates extracellular vesicles of epidermal keratinocytes, new research in Aging suggests. The disturbance of intercellular communication is one of the hallmarks of aging. In their new study, researchers from the University of Lyon, Toyo University and Gattefossé SAS aimed to clarify the …
- Dr. Mario E. Lacouture Named New Chief of Dermatology at NYU Langone Hospital--Long Islandhttps://practicaldermatology.com/news/dr-mario-e-lacouture-named-new-chief-of-dermatology-at-nyu-langone-hospital-long-island/2462164/Mario E. Lacouture, MD, has been named the new Chief of the Dermatology Division, Department of Medicine of NYU Langone Hospital--Long Island. Dr. Lacouture will receive an academic appointment as Professor of Medicine at NYU Grossman School of Medicine, and will serve as the Medical Director of t…
- NPs and PAs Value Prognostic Information From DecisionDx-Melanomahttps://practicaldermatology.com/news/nps-and-pas-value-prognostic-information-from-decisiondx-melanoma/2462163/More than 90% of nurse practitioners and physician assistants(NPs/PAs), agree that prognostic information about a patient’s melanoma is valuable and improves patient care, , according to new study looking at use of DecisionDx-Melanoma in the Journal of the Advanced Practitioner in Oncology. Cast…
- Taking a Joint Approach to Treating PsA and PsO: One Rheumatologist’s Advice on Working With Dermatologistshttps://practicaldermatology.com/news/taking-a-joint-approach-to-treating-psa-and-pso-one-rheumatologists-advice-on-working-with-dermatologists/2462158/Psoriasis (PsO) and psoriatic arthritis (PsA) often travel together, which is why dermatologists and rheumatologists need to collaborate and ensure that patients receive the best and most appropriate care for their skin and joints. Around one in three people with PsO also have PsA, according to th…
- AD Pipeline Watch: Rademikibart Maintains Efficacy Out to Week 52https://practicaldermatology.com/news/ad-pipeline-watch-rademikibart-maintains-efficacy-out-to-week-52/2462145/Connect Biopharma’s rademikibart continues to wow in patients with moderate-to-severe atopic dermatitis, according to topline results from the Stage 2 (maintenance period) of its China pivotal trial. Rademikibart is an inhibitory human monoclonal antibody against the IL-4Rα a common subunit for IL…